Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities (2017 - 2026)

Crinetics Pharmaceuticals' quarterly Gains from Investment Securities came in at -$20000.0 in Q1 2026, down 100.13% year-on-year from $15.3 million in Q1 2025, and down 147.62% quarter-over-quarter from $42000.0 in Q4 2025.

Crinetics Pharmaceuticals has reported Gains from Investment Securities for 10 years, with the latest figure at -$20000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Gains from Investment Securities fell 100.13% year-over-year to -$20000.0; the trailing twelve-month figure through Mar 2026 stood at $73000.0 (down 99.52% YoY), and the FY2024 full-year result was $13.7 million, up 8.23% from the prior year.
  • Gains from Investment Securities for Q1 2026 stood at -$20000.0, down from $42000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $46.3 million in Q4 2023, with the low at -$5.6 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $8.3 million, with a median of $4.1 million recorded in 2023.
  • Peak annual rise in Gains from Investment Securities reached 343359.55% in 2022, while the deepest fall reached 70100.0% in 2022.
  • Tracing CRNX's Gains from Investment Securities over 5 years: stood at -$5.6 million in 2022, then surged by 926.41% to $46.3 million in 2023, then sank by 99.89% to $51000.0 in 2024, then slipped by 17.65% to $42000.0 in 2025, then slumped by 147.62% to -$20000.0 in 2026.
  • The last three Gains from Investment Securities figures came in at -$20000.0 (Q1 2026), $42000.0 (Q4 2025), and $15.0 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Crinetics Pharmaceuticals 3.59 Bn 3.59 Bn 10.53 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -20,000.00
Mar 31, 2026 -20,000.00
Dec 31, 2025 42,000.00
Dec 31, 2025 42,000.00
Jun 30, 2025 14.99 Mn
Jun 30, 2025 14.99 Mn
Mar 31, 2025 15.29 Mn
Mar 31, 2025 15.29 Mn
Dec 31, 2024 51,000.00
Dec 31, 2024 51,000.00
Sep 30, 2024 5.00 Mn
Sep 30, 2024 5.00 Mn
Jun 30, 2024 14.14 Mn
Jun 30, 2024 14.14 Mn
Mar 31, 2024 13.80 Mn
Mar 31, 2024 13.80 Mn
Dec 31, 2023 46.28 Mn
Dec 31, 2023 46.28 Mn
Sep 30, 2023 12.46 Mn
Sep 30, 2023 12.46 Mn
Jun 30, 2023 3.23 Mn
Jun 30, 2023 3.23 Mn
Mar 31, 2023 100,000.00
Mar 31, 2023 100,000.00
Dec 31, 2022 -5.60 Mn
Dec 31, 2022 -5.60 Mn
Sep 30, 2022 8.90 Mn
Sep 30, 2022 8.90 Mn
Jun 30, 2022 2.53 Mn
Jun 30, 2022 2.53 Mn
Mar 31, 2022 1.65 Mn
Mar 31, 2022 1.65 Mn
Dec 31, 2021 8,000.00
Dec 31, 2021 8,000.00
Sep 30, 2021 2,591.00
Sep 30, 2021 2,591.00
Jun 30, 2021 1,901.00
Jun 30, 2021 1,901.00
Mar 31, 2021 100,000.00
Mar 31, 2021 100,000.00
Dec 31, 2020 -1,000.00
Dec 31, 2020 -1,000.00
Sep 30, 2020 4,224.00
Sep 30, 2020 4,224.00
Jun 30, 2020 1,019.00
Jun 30, 2020 1,019.00
Mar 31, 2020 3,869.00
Mar 31, 2020 3,869.00
Dec 31, 2019 7,000.00
Dec 31, 2019 7,000.00
Sep 30, 2019 9,119.00
Sep 30, 2019 9,119.00
Jun 30, 2019 773,125.00
Jun 30, 2019 773,125.00
Mar 31, 2019 2.92 Mn
Mar 31, 2019 2.92 Mn
Dec 31, 2018 2.41 Mn
Dec 31, 2018 2.41 Mn
Sep 30, 2018 2.29 Mn
Sep 30, 2018 2.29 Mn
Jun 30, 2018 2.27 Mn
Jun 30, 2018 2.27 Mn
Mar 31, 2018 -2,000.00
Mar 31, 2018 -2,000.00
Dec 31, 2017 838,276.00
Dec 31, 2017 838,276.00